Euglycemic diabetic ketoacidosis (euglycemic DKA) is a form of diabetic ketoacidosis where dangerous levels of acid build up in the blood, but blood sugar stays below 250 mg/dL. In classic DKA, blood sugar typically soars well above 250 mg/dL, which is often the first red flag that something is wrong. In the euglycemic variant, that warning sign is missing, making it harder to catch and easier to dismiss.
How It Differs From Classic DKA
Standard DKA is defined by three things happening at once: high blood sugar (above 250 mg/dL), high levels of ketones in the blood, and metabolic acidosis, meaning the blood becomes dangerously acidic. Euglycemic DKA has the same acidosis and the same ketone buildup, but blood glucose can be under 200 mg/dL. Some definitions use a cutoff of 250 mg/dL, though many clinicians prefer the stricter threshold of under 200 mg/dL along with blood ketone levels at or above 3.0 mmol/L and either a blood pH of 7.3 or lower, bicarbonate of 18 or lower, or an elevated anion gap.
The danger is identical. Your blood is still becoming acidic, your body is still breaking down fat at an unsustainable rate, and organ damage can still occur. The only difference is that the number on a glucose meter looks reassuringly normal.
Why Blood Sugar Stays Normal
In both forms of DKA, the core problem is that the body doesn’t have enough insulin relative to the hormones that raise blood sugar, especially glucagon. When that ratio tips, your body starts rapidly breaking down stored fat for energy instead of using glucose. The byproducts of that fat breakdown are ketones, which accumulate in the blood and make it acidic.
In classic DKA, the liver also pumps out extra glucose, driving blood sugar sky-high. In euglycemic DKA, something prevents that glucose spike. The most common reasons: the liver’s glucose reserves (glycogen) are already depleted from fasting or low carbohydrate intake, the kidneys are flushing out extra glucose through urine, or the person is still taking enough insulin to keep glucose in check but not enough to stop fat breakdown. This is why euglycemic DKA is sometimes described as a “partially treated DKA.” There’s just enough insulin to manage glucose but nowhere near enough to shut down the dangerous ketone production.
Common Triggers
SGLT2 Inhibitor Medications
The most widely recognized trigger today is a class of diabetes and heart failure medications called SGLT2 inhibitors, which includes canagliflozin, dapagliflozin, and empagliflozin. These drugs work by forcing the kidneys to excrete excess glucose into the urine. That glucose loss creates a state of carbohydrate starvation inside the body, even if the person is eating normally. The body responds by ramping up fat breakdown and ketone production. On top of that, SGLT2 inhibitors directly stimulate the pancreas to release more glucagon, worsening the hormonal imbalance that drives ketoacidosis. Blood sugar stays normal or low precisely because the drug is dumping glucose into the urine.
The FDA has required label warnings on all SGLT2 inhibitors stating that ketoacidosis can occur even when blood sugar is below 250 mg/dL. Manufacturers must also stop these medications before surgery: at least three days before for canagliflozin, dapagliflozin, and empagliflozin, and at least four days before for ertugliflozin.
Other Triggers
Euglycemic DKA can also develop during pregnancy, prolonged fasting, very low carbohydrate diets, heavy alcohol use, and acute illness with vomiting or reduced food intake. In each case, the common thread is carbohydrate deficit. The body runs low on its preferred fuel, insulin levels drop, and fat breakdown accelerates. Pregnancy is a particularly high-risk setting because the growing fetus constantly draws glucose from the mother’s blood, creating a natural tendency toward lower blood sugar and higher ketone production.
Symptoms and Why Diagnosis Gets Delayed
The symptoms of euglycemic DKA overlap heavily with classic DKA: nausea, vomiting, loss of appetite, rapid or labored breathing, fatigue, and abdominal pain. The rapid breathing happens because your body is trying to compensate for the acid in your blood by exhaling more carbon dioxide. You may also feel short of breath without any obvious lung problem.
The critical issue is that many people with diabetes, and even some clinicians, use blood sugar as the first screening tool for DKA. When glucose reads 120 or 150 mg/dL, the instinct is to look elsewhere for the cause of nausea or breathing difficulty. People on insulin may actually reduce their dose because their sugar looks fine, which worsens the ketone buildup. This delay in recognition is what makes euglycemic DKA particularly dangerous. By the time the correct diagnosis is made, the acidosis may be more advanced than it would have been if high blood sugar had triggered earlier testing.
How Serious Is It?
Classic DKA carries a mortality rate of roughly 0.65% to 3.3%. Euglycemic DKA is generally considered to have worse outcomes, largely because of delayed diagnosis. The most detailed mortality data comes from pregnant women, where maternal euglycemic DKA can increase the rate of fetal death to around 9% and raises the risk of serious complications including kidney injury, respiratory distress, preeclampsia, and coma. For SGLT2 inhibitor-related cases, specific mortality data is still being collected through an FDA-mandated five-year surveillance study.
How It’s Treated
Treatment for euglycemic DKA differs from standard DKA in one important way: because blood sugar is already normal or low, you can’t simply give insulin and let glucose fall. Instead, treatment involves a fixed-rate insulin drip to clear the ketones and resolve the acidosis, while simultaneously running sugar-containing IV fluids (dextrose) to prevent blood sugar from dropping dangerously low. The goal is to keep glucose in the range of 140 to 180 mg/dL while the insulin does its work clearing ketones.
This is a key distinction. In classic DKA, the insulin dose is adjusted based on how quickly blood sugar comes down. In euglycemic DKA, the insulin rate stays fixed regardless of glucose levels, and the dextrose drip is what gets adjusted up or down to keep blood sugar stable. Blood sugar is checked hourly throughout treatment. If it drops below 70 mg/dL, the insulin is paused and dextrose is given to bring it back up.
Resolution is defined by the acidosis clearing: the anion gap returning to normal (below 12), bicarbonate rising above 15 mmol/L, and blood sugar remaining under 200 to 250 mg/dL. At that point, the transition from IV to injectable insulin can begin.
Prevention for People on SGLT2 Inhibitors
If you take an SGLT2 inhibitor, the most important prevention strategy is knowing when to temporarily stop it. You should pause the medication any time you are acutely ill with vomiting, diarrhea, or fever, or any time you are not eating or drinking normally. Once you’ve been feeling better and eating and drinking normally for 24 to 48 hours, you can restart it.
Before any planned surgery, talk with your doctor about stopping the medication at least three to four days in advance. If you develop unexplained nausea, vomiting, fatigue, or difficulty breathing while taking one of these drugs, the possibility of euglycemic DKA should be considered even if your blood sugar looks normal. Home ketone testing strips (blood ketone meters are more reliable than urine strips) can help you catch a problem early when glucose readings would otherwise look reassuring.